{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:21:36Z","timestamp":1787628096468,"version":"build-2736575974"},"reference-count":64,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s355557","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T06:00:11Z","timestamp":1651557611000},"page":"333-355","source":"Crossref","is-referenced-by-count":13,"title":["Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Xiao Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ho","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7728-1347","authenticated-orcid":true,"given":"Matthew Jian Chun","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gkitzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui Yen","family":"Soh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Ying Khee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/j.ejca.2006.06.005","volume":"42","author":"Coebergh","year":"2006","journal-title":"Eur J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"ref3","unstructured":"CANCER.ORG. How is childhood leukemia classified?; 2020. Available from: https:\/\/www.cancer.org\/cancer\/leukemia-in-children\/detection-diagnosis-staging\/how-classified.html. Accessed April 20, 2022."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s10552-015-0657-6","volume":"26","author":"Katz","year":"2015","journal-title":"Cancer Causes Control"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref6","first-page":"3310","volume":"95","author":"Schrappe","year":"2000","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/leu.2008.251","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/jco.2009.22.2950","volume":"28","author":"Ko","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1097\/MPH.0b013e318290c3d6","volume":"35","author":"Reismuller","year":"2013","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0160310","DOI":"10.1371\/journal.pone.0160310","volume":"11","author":"Ceppi","year":"2016","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejca.2010.09.020","volume":"47","author":"von Stackelberg","year":"2011","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/ijh-2016-0001","volume":"5","author":"Maziarz","year":"2016","journal-title":"Int J Hematol Oncol"},{"key":"ref14","unstructured":"Hanson SBaSG. 2014 U.S. organ and tissue transplant cost estimates and discussion; 2020. Available from: https:\/\/us.milliman.com\/en\/Insight\/2014-usorgan-and-tissue-transplant-cost-estimates-and-discussion. Accessed April 20, 2022."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbmt.2007.12.493","volume":"14","author":"Nietfeld","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.bbmt.2018.05.009","volume":"24","author":"Dalle","year":"2018","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41409-020-01014-x","volume":"56","author":"Dalle","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.bbmt.2019.07.011","volume":"25","author":"Balduzzi","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref20","unstructured":"Novartis. Novartis receives approval for Kymriah\u00ae (tisagenlecleucel) by health sciences authority as Singapore\u2019s first commercially approved CAR-T therapy. Available from: https:\/\/www.novartis.com.sg\/news\/media-releases\/novartis-receives-approval-kymriah-tisagenlecleucel-health-sciences-authority.Accessed March 2021."},{"key":"ref21","unstructured":"Clinicaltrials.gov. Determine efficacy and safety of ctl019 in pediatric patients with relapsed and refractory b-cell all and high risk b-cell all at first relapse. Determine feasibility and safety of ctl019 therapy in pediatric patients with high risk b-cell all that relapsed < 6 months post all-hsCT. (ELIANA). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02435849. Accessed June 15, 2020."},{"key":"ref22","unstructured":"Dourthe M. Safety and efficacy of tisagenlecleucel (CLTl019) in B acute lymphoblastic leukemia in children and young adults: Rrobert Debr\u00e9 and Saint Louis hospitals experience. Presented at: HemaSphere; 2019; Amsterdam, The Netherlands: EHA. Available from: https:\/\/library.ehaweb.org\/eha\/2019\/24th\/267244\/andre.baruchel.safety.and.efficacy.of.tisagenlecleucel.28ctl01929.in.b.acute.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3. Accessed April 20, 2022."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dourthe M. Safety and efficacy of tisagenlecleucel (CLTl019) in B-cell acute lymphoblastic leukemia in children and young adults: the French experience. Presented at: Blood; 2019; Orlando, Florida: ASH.","DOI":"10.1182\/blood-2019-131123"},{"key":"ref24","unstructured":"Bader A. Real life experience in the treatment of pediatric, adolescent and young adult ALL patients using commercially available CAR-T cells. Presented at: 1st European CAR T Cell Meeting; 2019."},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Grupp S, Hu Z-H, Zhang Y, et al. Tisagenlecleucel Chimeric Antigen Receptor (car) t-cell therapy for relapsed\/refractory children and young adults with acute lymphoblastic leukemia (ALL): real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry. Presented at: Blood; 2019; ASH Annual Meeting; December 7\u201310; Orlando, Florida.","DOI":"10.1182\/blood-2019-129279"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Pasquini M, Hu ZH, Zhang Y. Real world experience of tisagenlecleucel Chimeric Antigen Receptor (CAR) T-cells targeting cd19 in patients with acute lymphoblastic leukemia (all) and diffuse large b-cell lymphoma (dlbcl) using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Presented at: Clinical Lymphoma, Myeloma & Leukemia; 2019. Available from: https:\/\/epostersonline.com\/soho2019\/node\/711?view=true. Accessed April 20, 2022.","DOI":"10.1016\/j.clml.2019.07.190"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/13696998.2021.1922066","volume":"24","author":"Wang","year":"2021","journal-title":"J Med Econ"},{"key":"ref28","unstructured":"Nicedsu.org.uk. Nice DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. TSD 19 (nicedsu.org.uk); 2017."},{"key":"ref29","unstructured":"Clinicaltrials.gov. Study of efficacy and safety of CTL019 in Pediatric ALL patients. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02228096. Accessed June 15, 2020."},{"key":"ref30","unstructured":"Clinicaltrials.gov. Phase I\/IIA study of cart19 cells for patients with chemotherapy resistant or refractory cd19+ leukemia and lymphoma (pedi cART19). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01626495. Accessed January 15, 2017."},{"key":"ref31","unstructured":"NICE. Single technology appraisal. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years [ID1167], committee papers; 2018. Available from: https:\/\/www.nice.org.uk\/guidance\/ta554\/documents\/committee-papers. Accessed June 6, 2020."},{"key":"ref32","unstructured":"CADTH. Canadian Agency for Drugs and Technologies in Health (CADTH) optimal use report. tisagenlecleucel for acute lymphoblastic leukemia: economic review report; 2020. Available from: https:\/\/cadth.ca\/sites\/default\/files\/pdf\/car-t\/op0538-tisagenlecleucel-economic-report-pALL-jan2019.pdf. Accessed April 20, 2022."},{"key":"ref33","unstructured":"MSAC. public summary document, tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL); 2019. Available from: http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/A2B10F9A03293BC8CA2583CF001C7A4D\/$File\/1519.1%20Final%20updated%20PSD%20Nov%2019_redacted.pdf. Accessed August 21, 2020."},{"key":"ref34","unstructured":"Agency for Care Effectiveness. ACE Clinical Guidance (ACG) process and methods; 2020. Available from: https:\/\/www.ace-hta.gov.sg\/our-process-and-methods.html. Accessed April 20, 2022."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1478-7547-1-8","volume":"1","author":"Hutubessy","year":"2003","journal-title":"Cost Eff Resour Alloc"},{"key":"ref36","unstructured":"Department of Statistics Singapore. Department of Statistics Singapore; 2020. Avaliable from: https:\/\/www.singstat.gov.sg\/modules\/infographics\/economy. Accessed April 20, 2022."},{"key":"ref37","unstructured":"MAS. Monetary authority of Singapore. Exchange rates; 2021. Available from: https:\/\/eservices.mas.gov.sg\/Statistics\/msb\/ExchangeRates.aspx. Accessed April 20, 2022."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-018-0117-0","volume":"8","author":"Gore","year":"2018","journal-title":"Blood Cancer J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-019-00910-z","volume":"36","author":"Bassan","year":"2019","journal-title":"Adv Ther"},{"key":"ref42","unstructured":"Department of Statistics Singapore. complete life tables for Singapore resident population, 2017\u20132018. Avalibale from: https:\/\/www.singstat.gov.sg\/publications\/population\/complete-life-table. Accessed June 12, 2020."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/pbc.20922","volume":"48","author":"MacArthur","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"ref44","unstructured":"NCCN Clinical Practice Guidelines in Oncology. pediatric acute lymphoblastic leukemia: version 2.2020; 2019. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx. Accessed April 20, 2022."},{"key":"ref45","unstructured":"NHS Network Site Specific Group (NSSG). Haematology. myeloid group - FLA-IDA; 2020. Available from: http:\/\/nssg.oxford-haematology.org.uk\/myeloid\/protocols\/ML-9-fla-ida.pdf. Accessed April 20, 2022."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2005.04.5856","volume":"24","author":"Gaynon","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jpeds.2007.07.006","volume":"151","author":"Svendsen","year":"2007","journal-title":"J Pediatr"},{"key":"ref48","unstructured":"HSA Product Information. Blincyto. Available from: https:\/\/myhealthbox.eu\/en\/view\/3625248\/8a63a97851d9c6b3780501cec3e7181a\/leaflet. Accessed June 24, 2020."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.21203\/rs.2.22855\/v1","volume":"20","author":"Phua","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1524-4733.2009.00579.x","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen MF, Cabases JM. Self-reported population health: an international perspective based on EQ-5D; 2014: 1\u2013196.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.11098","volume":"97","author":"Sung","year":"2003","journal-title":"Cancer"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21070","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol Assess"},{"key":"ref55","unstructured":"National Cancer Centre Singapore. Cancer incidence in Singapore. Available from: https:\/\/www.nccs.com.sg\/patient-care\/cancer-types\/cancer-statistics. Accessed June 12, 2020."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2012-02-265884","volume":"120","author":"Locatelli","year":"2012","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jval.2018.09.253","volume":"21","author":"Yang","year":"2018","journal-title":"Value Health"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/jnci\/djy193","volume":"111","author":"Sarkar","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"506e1","DOI":"10.1016\/j.jtct.2021.03.005","volume":"27","author":"Wakase","year":"2021","journal-title":"Cell Ther Transpl"},{"key":"ref61","unstructured":"The York Report. Exploring the assessment and appraisal of regenerative medicines and cell therapy products; 2016. Available from: http:\/\/docplayer.net\/18693201-Exploring-the-assessment-and-appraisal-of-regenerative-medicines-and-cell-therapy-products.html. Accessed June 6, 2020."},{"key":"ref62","unstructured":"Szende A, Janssen B, Cabases J Self-reported population health: an international perspective based on EQ-5D. Springer; 2014. Avaialbe from: https:\/\/link.springer.com\/content\/pdf\/10.1007%2F978-94-007-7596-1.pdf. Accessed April 20, 2022."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/pbc.25451","volume":"62","author":"Kelly","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.14965","volume":"180","author":"Kuhlen","year":"2018","journal-title":"Br J Haematol"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=80496","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=80496","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T06:00:20Z","timestamp":1651557620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/cost-effectiveness-and-budget-impact-analyses-of-tisagenlecleucel-in-p-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":64,"URL":"https:\/\/doi.org\/10.2147\/ceor.s355557","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}